STOCK TITAN
  1. Home
  2. News
  3. JNJ

Johnson & Johnson - JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.

In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.

Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.

With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.

News

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Rhea-AI Summary
Johnson & Johnson (JNJ) will host a conference call to review first-quarter results, featuring top executives. Investors can access the webcast and presentation material on the company's website. The press release provides details on accessing the call and future earnings calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
News

Johnson & Johnson Completes Acquisition of Ambrx

Rhea-AI Summary
Johnson & Johnson (JNJ) completes the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion, strengthening its commitment to innovation in prostate cancer. The acquisition deepens JNJ's pipeline of next-generation antibody drug conjugates (ADCs) and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
acquisition
-
News

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Rhea-AI Summary
Johnson & Johnson's RYBREVANT® Receives FDA Approval for First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations, Showing 61% Reduction in Disease Progression or Death in Phase 3 PAPILLON Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
fda approval
News

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

Rhea-AI Summary
Johnson & Johnson's TECVAYLI® receives FDA approval for biweekly dosing, offering flexibility to patients with relapsed or refractory multiple myeloma. The bispecific antibody targets BCMA and CD3, activating an immune response. The approval is based on the Phase 1/2 MajesTEC-1 study results, allowing reduced dosing frequency for patients achieving a complete response for six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News

Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference

Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference. Peter Menziuso will represent the Company in a session on March 13th, at 10:45 a.m. (Eastern Time) at the Loews Miami Beach Hotel. Investors can access the live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
-
News

Johnson & Johnson to Participate in the Leerink Global Biopharma Conference

Rhea-AI Summary
Johnson & Johnson (JNJ) to participate in Leerink Global Biopharma Conference with Joe Wolk, EVP, CFO representing the company. The live webcast will be available on their website for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
News

Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference. Ahmet Tezel, Company Group Chairman, MedTech R&D, will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). The live audio webcast will be available on the JNJ website. This indicates the company's focus on investor engagement and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
News

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) reported a 7.3% sales growth to $21.4 billion in the fourth quarter of 2023, with operational growth of 7.2% and adjusted operational growth of 5.7%. Earnings per share (EPS) increased by 39.3% to $1.70, and adjusted EPS increased by 11.7% to $2.29. The full-year reported sales grew by 6.5% to $85.2 billion, with operational growth of 7.4% and adjusted operational growth of 5.9%. The EPS for the full year decreased by 15.3% due to a special one-time charge in the first quarter, but the adjusted EPS increased by 11.1%. The company re-confirmed guidance for 2024 with operational sales growth of 5.0% - 6.0% and adjusted operational EPS of $10.55 - $10.75. Johnson & Johnson's regional sales and segment sales results also showed positive growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
earnings
-
News

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Rhea-AI Summary
Johnson & Johnson (JNJ) strengthens its commitment to oncology innovation by acquiring Ambrx Biopharma, Inc. (AMAM) in an all-cash merger transaction for approximately $2.0 billion. Ambrx's clinical and preclinical programs, including lead product candidate ARX517, a prostate-specific membrane antigen (PSMA)-targeting antibody drug conjugate (ADC), align with J&J's goal of developing next-generation ADCs and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
acquisition
News

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024

Rhea-AI Summary
Johnson & Johnson (NYSE: JNJ) declares a cash dividend of $1.19 per share for the first quarter of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
dividends earnings

FAQ

What is the current stock price of Johnson & Johnson (JNJ)?

The current stock price of Johnson & Johnson (JNJ) is $145.27 as of December 23, 2024.

What is the market cap of Johnson & Johnson (JNJ)?

The market cap of Johnson & Johnson (JNJ) is approximately 347.8B.

What are the main business segments of Johnson & Johnson?

Johnson & Johnson operates through three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products.

What recent developments have there been in Johnson & Johnson's pharmaceutical division?

Recently, Johnson & Johnson received expanded FDA approval for CARVYKTI®, a therapy for multiple myeloma, based on positive Phase 3 study results.

What products are included in Johnson & Johnson’s consumer health segment?

The consumer health segment includes products in baby care, beauty, oral care, over-the-counter drugs, and women's health.

What is CARVYKTI®?

CARVYKTI® is a one-time infusion therapy for multiple myeloma, recently approved for expanded use due to its efficacy in delaying disease progression.

What percentage of Johnson & Johnson's revenue is generated in the United States?

Over half of Johnson & Johnson’s total revenue is generated in the United States.

What is the focus of Johnson & Johnson’s medical devices segment?

The medical devices segment focuses on orthopedics, surgical instruments, and vision care.

What changes are happening with Johnson & Johnson’s consumer health division?

The consumer health division is being divested in 2023 and will operate under the new name Kenvue.

How does Johnson & Johnson contribute to global healthcare?

Johnson & Johnson develops innovative solutions to prevent, treat, and cure complex diseases, aiming to improve global health.

Where can I find more information about Johnson & Johnson?

More information about Johnson & Johnson can be found on their official website at www.jnj.com.

What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?

The pharmaceutical division focuses on immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases.

Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#25 Ranked by Market Cap
#945 Ranked by Dividends

JNJ Stock Data

347.83B
2.41B
0.09%
73.15%
0.73%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW BRUNSWICK